Prevalence of and factors associated with hepatic steatosis in patients coinfected with hepatitis C virus and HIV: Agence Nationale pour la Recherche contre le SIDA et les hépatites virales CO3 Aquitaine Cohort

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 2, 2007, Pages 168-173

  Neau, Didier ^a   Winnock, Maria ^b   Castéra, Laurent ^c,g   Bail, Brigitte Le ^d   Loko, Marc Arthur ^b   Géraut, Laurent ^a   Dupon, Michel ^a   Ragnaud, Jean Marie ^a   Lacoste, Denis ^a,e   Lafon, Marie Edith ^f   Bioulac Sage, Paulette ^d   Dabis, François ^a,b   Chene G ^l,l   Dabis, F ^l,l   Dupon, M ^g,l,l   Longy Boursier, M ^g,l   Morlat, P ^g,l,l   Pellegrin, J L ^g,l   Ragnaud, J M ^g,l   Salamon, R ^l   Thiebaut R ^l,l   Lewden, C ^l   Lawson Ayayi, S ^l   Mercie P ^g,l   Moreau, J F ^g,l   Bernard, N ^g,l   Lacoste, D ^g,l   Malvy, D ^g,l   Neau, D ^g,l   Blaizeau, M J ^l   Decoin, M ^l   Delveaux, S ^l   Hannapier, C ^l   Labarrere S ^l   Lavignolle Aurillac, V ^l   Uwamaliya Nziyumvira, B ^l   Palmer, G ^l   Touchard, D ^l   Winnock, M ^l   Balestre, E ^l   Alioum, A ^l   Jacqmin Gadda, H ^l   Bonarek, M ^g   Bonnet, F ^g   Gellie, P ^g   Lacombe, K ^g   Dauchy, F ^g   Dutronc, H ^g   Lafarie, S ^g   Pistonne, T ^g   Thibaut, P ^g   Chambon, D ^g   De La Taille, C ^g   Cazorla, C ^g   Galperine, T ^g   Ochoa, A ^g   Viallard, J F ^g   Caubet, O ^g   Lazaro, E ^g   Nouts, C ^g   Couzigou, P ^g   Fleury, H ^g   Lafon, M E ^g   Masquelier, B ^g   Pellegrin, I ^g   Breilh, D ^g   Blanco, P ^g   Loste, P ^h   Caunegre L ^h   Bonnal, F ⁱ   Farbos, S ⁱ   Gemain, M C ⁱ   Ceccaldi, J ^j   Tchamgoue S ^j   De Witte, S ^k   more..

^a HÔPITAL PELLEGRIN   (France)

^b INSERM   (France)

^c HAUT LÉVÊQUE HOSPITAL   (France)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e HÔPITAL SAINT ANDRÉ   (France)

^f University Victor Segalen   (France)

^g BORDEAUX UNIVERSITY HOSPITAL   (France)

^h Department of Infectious Diseases Dax Hospital   (France)

ⁱ Bayonne Medical Center   (United States)

^j Libourne Hospital   (France)

^k Centre Hospitalier de Mont de Marsan   (France)

^l NONE

more..

Author keywords

Chronic hepatitis C; Hepatic steatosis; Hepatitis C virus infection; HIV infection

Indexed keywords

ADULT; ARTICLE; BODY MASS; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; FATTY LIVER; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; LIVER CELL; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; STATISTICAL SIGNIFICANCE;

EID: 34249869301     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318042e1db     Document Type: Article

References (38)

1. Rosenthal E, Poiree M, Pradier C, et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France (Mortavic 2001 study). AIDS. 2003;17:1803-1809.
2. Marcellin P, Asselah T, Boyer N. Fibrosis and disease progression in hepatitis C. Hepatology. 2002;36:S47-S56.
3. Sulkowski MS, Thomas DL. Hepatitis C in the HIV-infected person. Ann Intern Med. 2003;138:197-207.
4. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18:2285-2293.
5. Soriano V, Sulkowski M, Bergin C, et al. Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV-HCV International Panel. AIDS. 2002;16:813-828.
6. Soto B, Sanchez-Quijano A, Rodrigo L, et al. Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. J Hepatol. 1997;26:1-5.
7. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet. 1997;349:825-832.
8. Poynard T, Ratziu V, Charlotte F, et al. Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis C. J Hepatol. 2001;34:730-739.
9. Roudot-Thoraval F, Bastie A, Pawlotsky JM, et al. Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus. Hepatology. 1997;26:485-490.
10. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis. 2001;21:3-16.
11. Burt AD, Mutton A, Day CP. Diagnosis and interpretation of steatosis and steatohepatitis. Semin Diagn Pathol. 1998;15:246-258.
12. Castera L, Chouteau P, Hezode C, et al. Hepatitis C virus-induced hepatocellular steatosis. Am J Gastroenterol. 2005;100:711-715.
13. Adinolfi LE, Gambardella M, Andreana A, et al. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33:1358-1364.
14. Castera L, Hezode C, Roudot-Thoraval F, et al. Worsening of steatosis is an independent factor of fibrosis progression in untreated patients with chronic hepatitis C and paired liver biopsies. Gut. 2003;52:288-292.
15. Fartoux L, Chazouilleres O, Wendum D, et al. Impact of steatosis on progression of fibrosis in patients with mild hepatitis C. Hepatology. 2005;41:82-87.
16. Hourigan LF, Macdonald GA, Purdie D, et al. Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis. Hepatology. 1999;29:1215-1219.
17. Rubbia-Brandt L, Fabris P, Paganin S, et al. Steatosis affects chronic hepatitis C progression in a genotype-specific way. Gut. 2004;53:406-412.
18. Moriya K, Yotsuyanagi H, Shintani Y, et al. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. J Gen Virol. 1997;78:1527-1531.
19. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients. J Hepatol. 2004;40:484-490.
20. Poynard T, Ratziu V, McHutchison J, et al. Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology. 2003;38:75-85.
21. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol. 2000;33:106-115.
22. Castera L, Hezode C, Roudot-Thoraval F, et al. Effect of antiviral treatment on evolution of liver steatosis in patients with chronic hepatitis C: indirect evidence for a role of HCV genotype 3 in steatosis. Gut. 2004;53:420-424.
23. Kumar D, Farrell GC, Fung C, et al. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after sustained therapeutic response. Hepatology. 2002;36:1266-1272.
24. Rubbia-Brandt L, Giostra E, Mentha G, et al. Expression of liver steatosis in hepatitis C virus infection and pattern of response to alpha-interferon. J Hepatol. 2001;35:307.
25. Ristig M, Drechsler H, Powderly WG. Hepatic steatosis and HIV infection. AIDS Patient Care STDS. 2005;19:356-365.
26. Lonergan JT, Behling C, Pfander H, et al. Hyperlactatemia and hepatic abnormalities in 10 human immunodeficiency virus-infected patients receiving nucleoside analogue combination regimens. Clin Infect Dis. 2000;31:162-166.
27. Binquet C, Chêne G, Jacqmin-Gadda H, et al. Modeling changes in CD4-positive T-lymphocytes counts after the start of antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997. Am J Epidemiol. 2001;153:386-393.
28. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996;24:289-293.
29. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS. 2005;19:585-592.
30. Monto A, Dove LM, Bostrom A, et al. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology. 2005;42:310-316.
31. Marks KM, Petrovic LM, Talal AH, et al. Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus. J Infect Dis. 2005;192:1943-1949.
32. Bani-Sadr F, Carrat F, Bedossa P, et al. Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors. AIDS. 2006;20:525-531.
33. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol. 2006;44:1026-1032.
34. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis. 2006;43:365-372.
35. Browning JD, Szczepaniak LS, Dobbins R, et al. Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity. Hepatology. 2004;40:1387-1395.
36. Asselah T, Boyer N, Guimont MC, et al. Liver fibrosis is not associated with steatosis but with necroinflammation in French patients with chronic hepatitis C. Gut. 2003;52:1638-1643.
37. Neuman MG, Benhamou JP, Malkiewicz IM, et al. Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat. 2002;9:134-140.
38. Okuda M, Li K, Beard MR, et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology. 2002;122:366-375.